{"id":65,"date":"2018-06-25T10:13:39","date_gmt":"2018-06-25T09:13:39","guid":{"rendered":"http:\/\/blogs.kent.ac.uk\/mspvpuprepare\/?p=65"},"modified":"2018-06-25T10:20:23","modified_gmt":"2018-06-25T09:20:23","slug":"nigel-tempertons-research-on-influenza-pseudotypes-profiled-in-microbiology-today","status":"publish","type":"post","link":"https:\/\/blogs.kent.ac.uk\/mspvpuprepare\/2018\/06\/25\/nigel-tempertons-research-on-influenza-pseudotypes-profiled-in-microbiology-today\/","title":{"rendered":"Nigel Temperton’s research on influenza pseudotypes profiled in Microbiology Today"},"content":{"rendered":"

My research on pseudotyping influenza HA and NA onto lentiviral cores has been profiled in the Microbiology Society magazine, Microbiology today<\/a>. You can read the full text here<\/a>.<\/p>\n

Viral Pseudotype Unit<\/strong><\/h4>\n

\"\"<\/p>\n

Expertise at the University of Kent in pseudotype technology led to the creation, in 2011, of the Viral Pseudotype Unit (VPU). The VPU acts as an interface between academia, industry, and animal and public health laboratories, with the purpose of translating basic virus research into\u00a0in vitro<\/em>\u00a0cell culture pseudotype-based assays that can be readily employed for the characterisation of vaccines, antivirals and therapeutic antibodies. This has led to the use of pseudotype assays in the following broad R&D areas: immunogenicity testing of current and preclinical viral vaccines including new \u2018universal\u2019 vaccine prototypes; screening of monoclonal antibodies to isolate those that broadly neutralise across multiple subtypes\/species of the same virus; characterisation of antibody standards for serological assays; study of virus restriction factors (entry); and drug screening\/resistance studies.<\/p>\n